Denosumab

Definition

A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.

Also known as AMG 162, AMG-162, DENOSUMAB, Denosumab Biosimilar MW032, Denosumab Biosimilar QL1206, Denosumab Biosimilar TK-006, Prolia, Ranmark, TK-006, Xgeva — per NCIT

Also identified as

• ATC M05BX04 per RXNORM
• NCIT NCIT:C61313 per NCIT
• SCTID 446321003 per RXNORM
• SCTID 446457007 per RXNORM
• UNII 4EQZ6YO2HI per RXNORM

Indications